Clinical and economic burden of pneumonia among adults in Latin America.
The clinical and economic burden of adult community-acquired pneumonia (CAP) in Latin America is not well known. We conducted a literature review to describe the etiology, incidence, hospitalization, morbidity and mortality, antibiotic resistance, costs associated with care, and the potential benefits of pneumococcal vaccination in the reduction of adult CAP in Latin America. Data that were published during the period from January 1970 through August 2008 were identified via the Web sites and databases of the Pan American Health Organization, Latin American health agencies, and the US National Institutes of Health, National Library of Medicine (MEDLINE). Streptococcus pneumoniae was identified as the most common pathogen, accounting for up to 35% of CAP cases. The mean rate of CAP due to penicillin-resistant S. pneumoniae was 39%. The mortality in Latin America due to lower respiratory tract infections has been reported to be 6%, compared with 4% in developed regions, and CAP was the third most frequent cause of death in adults in 31 Latin American countries in 2001-2003. Although S. pneumoniae caused the majority of CAP, similar to other regions of the world, mortality due to CAP in Latin America was substantially greater than that in developed countries. This review demonstrates the need to facilitate standardized surveillance and reporting systems to monitor the burden of CAP and to implement prevention strategies to decrease the clinical and economic burden of CAP in Latin American adults.
Isturiz
Raul E
RE
Department of Medicine, Centro Médico de Caracas and Centro Médico Docente La Trinidad, Edificio Anexo A, Sótano 3, San Bernardino, Caracas 1011, Venezuela. risturiz7@hotmail.com
Luna
Carlos M
CM
Ramirez
Julio
J
D000328:Adult; D024881:Drug Resistance, Bacterial; D006760:Hospitalization; D006801:Humans; D015994:Incidence; D007843:Latin America / Q000453:epidemiology; D022242:Pneumococcal Vaccines / Q000627:therapeutic use; D011014:Pneumonia / Q000191:economics* / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control; D013296:Streptococcus pneumoniae / Q000187:drug effects / Q000276:immunology
D022242:Pneumococcal Vaccines